Sentences with phrase «presenting cells in the tumor»

«We are excited to be a part of this important new initiative to develop novel treatment options for patients,» said Ovid Trifan, M.D., Ph.D., chief medical officer of Apexigen, Inc. «APX005M is a potential best - in - class CD40 agonist that works by activating the immune system's antigen - presenting cells in the tumor microenvironment.

Not exact matches

«There was this initial thought that [circulating tumor cells] are only present at late stage,» says Sollier - Christen, but she notes that in the past year, several studies using more sensitive techniques have found such cells much earlier in tumor development, even before the tumor becomes visible by conventional imaging techniques.

When tumor cells are present in an environment that lacks oxygen and nutrients, they receive a signal that it is time for the cells to move to a different part of the body.

One type of cell, the polymorphonuclear myeloid - derived suppressor cell (PMN - MDSC), was present exclusively in the induced tumors.

Since the cancer cells in both types of tumors were the same, the researchers compared the noncancerous cells present in the induced and transplanted tumors to explore what might be causing the T cell apoptosis.

«Different types of cancer cells with different strengths and weaknesses are both present in the tumor at the same time and can work together to spread faster and more efficiently.

The drug causes tumor cells with a certain mutation — present in about 60 percent of melanomas — to commit suicide.

When present in tumors, both abnormal myc and abnormal mTOR are known to be able to rev up protein production and to foster cell growth.

Desgrosellier said the team will follow up with mouse models containing tumor fragments from patients to better reflect the diversity of cell types present in human disease.

«Despite the identification of circulating tumor cells (CTCs) and cell - free DNA (cfDNA) as biomarkers capable of providing clinically relevant information in cancer patients, at present their identification is not routinely used in clinical practice,» explains Silvia Morbelli, MD, PhD, of the IRCCS San Martino — IST National Cancer Research Institute and University of Genoa in Genoa, Italy.

In a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyIn a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyin the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyin the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyin the body).

Researchers had known that the IGF2BP3 protein is present in cancerous cells and tumors, but the protein's function was unknown until now.

In our mice, we observed the nearly - complete disappearance of already - present tumor cells in the organs.&raquIn our mice, we observed the nearly - complete disappearance of already - present tumor cells in the organs.&raquin the organs.»

When the protein is present, these cells that start out round and stuck together in a pattern resembling cobblestones become irregularly shaped and tend to detach from the tumor site in an uncoordinated way — hallmarks of metastasis.

Drugs like pembrolizumab boost the response in tumors where immune cells are present but don't work in tumors where there is no immune response to boost.

Once it «parked,» an enzyme present in pancreatic cancer caused the carrier to biodegrade, allowing the therapeutic cargo to be released at the correct address — the tumor cells.»

If tumor cells are not present in the sentinel node, the primary tumor most likely has not spread to lymph nodes or other organs.

BCL - 2 is present in high amounts in many tumors and helps cancer cells to survive, but when the BCL - 2 gene is blocked by MM41 in mice, the cancer cells succumb to apoptosis and die.»

Mechanistic studies showed that IFN increases antitumor immune responses by enhancing antigen presentation to T cells by dendritic cells present in the tumor microenvironment.

Potential uses Having been replicating in labs around the world for six decades, HeLa cells have also accrued errors not present in the original tumor DNA.

«A way to stabilize haploidy in animal cells: Mammalian haploid cells present problems during mitosis that limit their viability; the removal of the p53 tumor suppressor gene increases the survival rate of these cells thereby stabilising their haploid state.»

PDGFRα is a cell surface tyrosine kinase receptor involved in organ development and tumor progression, it is present in multiple cell types such as mesenchymal cells, neurons, astrocytes, megakaryocytes and oligodendrocyte progenitor.

Singlet oxygen tends to rip apart tumor cells in a manner that exposes many new tumor antigens to immune cells called dendritic cells, which, like police executing a dragnet, grab the antigens and present them to T cells for closer inspection.

Among lung cancer patients; suicide SMR was higher in males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), older patients (70 - 75 years; SMR = 12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR = 11.2), patients presenting with metastatic disease (SMR = 13.9) and in patients who refused to receive surgical treatment (SMR = 13).

To their surprise, the mutations that had made their lab - grown cells resistant to ADZ8055 were present in some patients» tumors even before treatment.

Researchers have found a group of circulating tumor cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

Knowing that they have been present in human relatives since prehistoric times could shed light on how the tumors co-opt an ancient molecular pathway in our cells to grow.

Overall, including all genomic variations present in most if not all tumor cells (clonal) as well as those present only in subsets of the cancer cells (subclonal) from tumor tissue, the researchers detected a total of 864 genetic changes in tissue samples across the three tumor types, and 627 (73 %) of those were also found in the blood.

Lymphomas are cancers of immune cells that may have arisen from lymphatic tissue present in the breast tumors transplanted into the mice.

«We have found that 10 % of colon and stomach tumors present the loss of a molecule called TP53TG1, whose function in healthy cells is to prevent activation of YBX1 protein.

It is thought that cancer cells seed the bloodstream late in cancer progression, when large tumors are present.

Bone marrow transplantation (hematopoetic stem cell transplantation) can also be considered immunotherapy because the donor's immune cells will often attack the tumor or cancer cells that are present in the host.

One of the fundamental weaknesses in the present treatment of cancer is the ability of tumor cells to endure stress under conditions of metabolic deprivation or chemotherapy.

The prevailing notion was that tumors had from a few hundred up to 20,000 genetic alterations that were not present in the patientembers healthy cells.

Assuming that all mutations are heterozygous (which is likely), the observed allele frequencies suggest that shared mutations are present in virtually all tumor cells.

«Cells expressing each of these characteristics were identified across all tumors, suggesting cells sensitive or resistant to chemotherapy are both presents in the same tumor,» confirmed SteCells expressing each of these characteristics were identified across all tumors, suggesting cells sensitive or resistant to chemotherapy are both presents in the same tumor,» confirmed Stecells sensitive or resistant to chemotherapy are both presents in the same tumor,» confirmed Stewart.

In all negative tumors, occasional positive tumor cells or coexisting reactive lymphocytes were present and served as internal positive controls (arrows in C, rightIn all negative tumors, occasional positive tumor cells or coexisting reactive lymphocytes were present and served as internal positive controls (arrows in C, rightin C, right).

A heterozygous founder mutation, for example, would be present in virtually all tumor cells and have a mutation frequency of 50 % in diploid cells.

In the latest issue of the magazine EBioMedicine researchers at SciLifeLab / Uppsala University present a biobank with cell lines that can be used as models for brain tumors.

CRI will present the 2016 William B. Coley Award for Distinguished Research in Tumor Immunology to Ton N. Schumacher, Ph.D., for his contributions to our understanding of how immune cells identify and target tumor - specific neoantigens, and how this capability can provide anti-tumor immuTumor Immunology to Ton N. Schumacher, Ph.D., for his contributions to our understanding of how immune cells identify and target tumor - specific neoantigens, and how this capability can provide anti-tumor immutumor - specific neoantigens, and how this capability can provide anti-tumor immutumor immunity.

PD - 1 is a receptor present on activated T cells, which mediates immunosuppression primarily in peripheral tissues, where PD - 1 ligands, PD - L1 and PD - L2 share an immunosuppressive activity and may be produced by either tumor cells or stromal / tumor - infiltrating immune cells.

The recently discovered protein NUDT5 is now presented as a candidate target for development of breast cancer treatment after being demonstrated to stop breast tumor cell growth in laboratory experiments.

Sixty metabolites were present in tumor cells, but not in benign tissue.

The specific antigen approach uses selected antigens that are also present in the patient's tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

However, in the present study there is no evidence of untoward donor cell proliferation or tumor formation up to at least 130 days post-transplantation, suggesting that cell division is a regulated or balanced event.

We also found that the EphB4 receptor expressed on the surface of breast cancer cells can promote tumor xenograft growth by enhancing blood vessel formation through interactions with its preferred ligand, ephrin - B2, present in tumor endothelial cells.

It may be that the FLT3 ITD mutation was not present in all tumor cells; perhaps it was introduced later than the others.

The accuracy of next - generation sequencing (NGS) for detecting tumor - specific mutations in plasma DNA is hindered by errors introduced during PCR / sequencing, base substitutions caused by DNA damage, and pre-existing mutations in normal cells that are present at a low frequency.

They looked for correlations between specific mutations in the tumor cells and the composition of the tumor microbiome — the types of bacteria present in the tumor's immediate environment and their relative abundance — and found relationships between the two.

They also plan to evaluate whether colorectal tumor microbiome composition can be assayed from stool samples, and if this data can also be used to predict the type of mutations present in the tumor cells.